Literature DB >> 30538119

Tamoxifen calms down the distressed PDAC stroma.

Maren Pein1,2,3, Thordur Oskarsson1,2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30538119      PMCID： PMC6322357          DOI： 10.15252/embr.201847334

Source DB:  PubMed          Journal:  EMBO Rep        ISSN： 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  8 in total

Review 1.  Remodelling the extracellular matrix in development and disease.

Authors:  Caroline Bonnans; Jonathan Chou; Zena Werb
Journal:  Nat Rev Mol Cell Biol       Date:  2014-12       Impact factor: 94.444

Review 2.  Tamoxifen: a most unlikely pioneering medicine.

Authors:  V Craig Jordan
Journal:  Nat Rev Drug Discov       Date:  2003-03       Impact factor: 84.694

Review 3.  Emerging roles of GPER in diabetes and atherosclerosis.

Authors:  Matthias Barton; Eric R Prossnitz
Journal:  Trends Endocrinol Metab       Date:  2015-03-09       Impact factor: 12.015

4.  Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

Authors:  Kenneth P Olive; Michael A Jacobetz; Christian J Davidson; Aarthi Gopinathan; Dominick McIntyre; Davina Honess; Basetti Madhu; Mae A Goldgraben; Meredith E Caldwell; David Allard; Kristopher K Frese; Gina Denicola; Christine Feig; Chelsea Combs; Stephen P Winter; Heather Ireland-Zecchini; Stefanie Reichelt; William J Howat; Alex Chang; Mousumi Dhara; Lifu Wang; Felix Rückert; Robert Grützmann; Christian Pilarsky; Kamel Izeradjene; Sunil R Hingorani; Pearl Huang; Susan E Davies; William Plunkett; Merrill Egorin; Ralph H Hruban; Nigel Whitebread; Karen McGovern; Julian Adams; Christine Iacobuzio-Donahue; John Griffiths; David A Tuveson
Journal:  Science       Date:  2009-05-21       Impact factor: 47.728

5.  Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.

Authors:  Bryan W Miller; Jennifer P Morton; Mark Pinese; Grazia Saturno; Nigel B Jamieson; Ewan McGhee; Paul Timpson; Joshua Leach; Lynn McGarry; Emma Shanks; Peter Bailey; David Chang; Karin Oien; Saadia Karim; Amy Au; Colin Steele; Christopher Ross Carter; Colin McKay; Kurt Anderson; Thomas R Jeffry Evans; Richard Marais; Caroline Springer; Andrew Biankin; Janine T Erler; Owen J Sansom
Journal:  EMBO Mol Med       Date:  2015-08       Impact factor: 12.137

6.  Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.

Authors:  Hanane Laklai; Yekaterina A Miroshnikova; Michael W Pickup; Eric A Collisson; Grace E Kim; Alex S Barrett; Ryan C Hill; Johnathon N Lakins; David D Schlaepfer; Janna K Mouw; Valerie S LeBleu; Nilotpal Roy; Sergey V Novitskiy; Julia S Johansen; Valeria Poli; Raghu Kalluri; Christine A Iacobuzio-Donahue; Laura D Wood; Matthias Hebrok; Kirk Hansen; Harold L Moses; Valerie M Weaver
Journal:  Nat Med       Date:  2016-04-18       Impact factor: 53.440

7.  Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes.

Authors:  Rhonda Hattar; Ori Maller; Shauntae McDaniel; Kirk C Hansen; Karla J Hedman; Traci R Lyons; Scott Lucia; R Storey Wilson; Pepper Schedin
Journal:  Breast Cancer Res       Date:  2009-01-27       Impact factor: 6.466

Review 8.  Genetics and biology of pancreatic ductal adenocarcinoma.

Authors:  Haoqiang Ying; Prasenjit Dey; Wantong Yao; Alec C Kimmelman; Giulio F Draetta; Anirban Maitra; Ronald A DePinho
Journal:  Genes Dev       Date:  2016-02-15       Impact factor: 11.361
  8 in total
  1 in total

Review 1.  Reprogramming of Mesothelial-Mesenchymal Transition in Chronic Peritoneal Diseases by Estrogen Receptor Modulation and TGF-β1 Inhibition.

Authors:  Robert B Wilson; Rami Archid; Marc A Reymond
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.